No Data
No Data
Genscript Bio (01548): Legend Biotech announced positive overall survival results for the key CARTITUDE-4 Phase III trial for the treatment of multiple myeloma.
Genscript Bio (01548) announced that Legend Biotech (NASDAQ: LEGN) plans to list on a US stock exchange.
Legend Biotech's CARVYKTI Triumphs in Phase 3 Trial
J&J Says Carvykti Beat Standard Drugs in Late-stage Blood Cancer Trial
Express News | Legend Biotech Corp - Safety Results Were Consistent With Established Safety Profile of Carvykti(®), and No New Safety Signals Were Identified
Express News | Legend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 Cartitude-4 Trial in Multiple Myeloma
Here's Why Legend Biotech (NASDAQ:LEGN) Can Manage Its Debt Despite Losing Money
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor